AbbVie's Parkinson's disease drug meets main goal in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on Monday. The study tested the safety and efficacy of flexible doses of the drug,
Hope for Parkinson’s disease symptoms is found in late-stage drug study
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, late-stage study showed that the drug significantly improved the ability of patients to manage daily tasks such as walking and eating.
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom improvement and safety.
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease.
AbbVie Says Phase 3 TEMPO-2 Study Of Tavapadon In Early Parkinson's Disease Met Main Goal
Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal. In the
AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study -- Update
AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 flexible-dose monotherapy trial,
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
AbbVie ABBV announced positive top-line results from the pivotal phase III TEMPO-2 study, which evaluated its recently acquired investigational drug tavapadon in adults with early Parkinson’s disease (PD).
Crain's Chicago Business20h
After one disappointment, AbbVie gets good news out of Cerevel buy
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
Betting Big On AbbVie: A Prescription For Growth And Dividends
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...
BioSpace2d
A Month After Stunning Schizophrenia Fail, AbbVie’s Other Cerevel Asset Shines Again
Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...
Outsourcing-pharma1d
AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3 results
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
clinicaladvisor.com1d
Tavapadon Beneficial for Early Parkinson Disease in Flexible-Dose Trial
Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...
AbbVie reports ‘positive’ results from Phase 3 TEMPO-2 trial
AbbVie (ABBV) announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose ...